Electronic Clinical Outcome Assessment (eCOA) Solutions Market Growth Is Expected To Reach USD 2.16 Billion By 2025

The complexity in healthcare information management is anticipated to fuel the demand for eCOA solutions in coming years. These solutions deliver accurate and timely health information and reduce burden of patients enrolled in clinical trials. 

eCOA measures overall mental state, patient symptoms, and the progression of a disease. Electronic diaries and electronic Patient Reported Outcomes (ePRO) are a part of eCOA platforms. Electronic diaries help document patient response. These are used as support systems for ePRO. In all the applications of clinical outcome assessment systems, the compliance rates are more than 90%, which helps accelerate research procedures. 

In addition, assessment systems help detect probable adverse conditions in advance for patients, which is crucial for taking preventive measures to avoid adverse effects in future. The ePRO platforms transfer real-time data from the patients to healthcare professionals for accurate decision-making and better evaluation of a patient’s health. Thus, the adoption of these platforms is expected to grow in near future. 

Growing adoption of software solutions during research studies, high R&D expenditure by pharmaceutical companies, favorable government grants to support clinical trials, and widening base of potential customers are some of the key contributing factors for market growth.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest: 

• Rising adoption of technologically advanced wearable and handheld medical devices helps capture clinical outcomes electronically, further making the medical information assessment easier
• The core advantage of web-based services is ability to access information from remote locations using only one computer or monitoring device in healthcare settings
• Cloud-based solutions are anticipated to grow at an exponential rate owing to integrated features that include flexibility, high accessibility, negligible handling costs, and easy data backup
• Contract research organizations dominated the market as major pharmaceutical companies are focused on reducing expenditure on clinical trials
• North America held the largest market share owing to the local presence of well-established market players coupled with large number of ongoing research in this region
• Asia Pacific market is expected to show fastest growth over the forecast period owing to the availability of a large number of contract research firms offering eCOA platforms to large pharmaceuticals
• The companies are making significant investments to implement eClinical solutions in order to manage medical information, owing to the benefits it offers 

Click Here For Reference : https://goo.gl/fu7oVu

Structural Heart Devices Market Worth Is Expected To Reach USD 9.1 Billion By 2025

The market is expected to witness an exponential growth over the next 8 years due to the rapid increase in cardiovascular conditions and increasing power of healthcare expenditure.

The defects are mostly present at birth, thereby directly affecting the under-5 mortality rate of a country. Therefore, rigorous actions are being undertaken by various government bodies across the globe to increase access to treatment. The Centers for Disease Control and Prevention have a public action plan to efficient management of cardiac conditions.

In addition, other organizations are working on improving the scenario for structural heart diseases treatment. For instance, in November 2016, the Cardiovascular Research Foundation (CRF) announced a launch of a journal focusing on diagnosis and treatment of structural heart defects. It was titled Structural Heart: The Journal of the Heart Team and is expected to be launched in May 2017. This is expected to trigger research & development activities along with capital invested in this field, resulting in technological advancements.

View summary of this report, Click Here 

Further key findings from the study suggest:

• Surgical Aortic Valve Replacement (SAVR) dominated the market in 2016, closely followed by Transcatheter Aortic Valve Replacement (TAVR). It can be attributed to the longest presence of the technique in the treatment regimen of aortic stenosis
• Left Atrial Appendage Closure (LAAC) is anticipated to be one of the fastest growing segment owing to the minimally invasive nature of the procedure. It also helps in reduction of risk of stroke, thus is projected to have a higher demand
• Geographically, North America held the largest market share in 2016 and is expected to maintain its position during the forecast period. High prevalence of cognitive heart diseases is the key reason for this dominance. Moreover, the mandatory CCHD screening for newborns imposed by the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP) in September 2014 also contributes to the growth in this region
• Asia Pacific is also expected to witness a rapid growth over the forecast period. The improved access and capability for treatments in this region is the key reason for this growth
• Some of the key players are Medtronic, ST. JUDE MEDICAL, Boston Scientific Corporation, CardioKinetix, Comed BV, Edwards Lifesciences Corporation, LivaNova PLC, Abbott Laboratories, JenaValve Technology, Inc., and Biomerics.

Click Here For Access Full Report : https://goo.gl/CFJr35

Electronic Health Records (EHR) Market Growth Is Expected To Reach USD 33.41 Billion By 2025

The government initiatives undertaken in support of EHR adoption are most likely to accentuate the market growth. 

The federal government introduced Health Information Technology for Economic and Clinical Health (HITECH) Act in 2009 for promoting usage of EHR amongst healthcare providers. The program included provision of training and assistance for health information technology (IT) workers in order to set up EHRs in the hospitals. 

The National Health Services (NHS), UK is planning to convert the documentation process into digitized form completely by the year 2018. In the U.S., federal government has announced financial incentives for physicians planning to adopt EHR systems. Any average physician with at least 30% of his/her patients covered with Medicare is eligible for incentives worth USD 44,000. 

Many region-specific initiatives are promoting eHealth services. For instance, EUR-Lex gave eHealth action plan for 2012 – 2020, which states the strategies for deployment of eHealth services amongst European nations. 

View summary of this report, Click Here

Further Key Findings From The Report Suggest:

• Web-based EHR was observed to be the largest product segment owing to the fact that it can be deployed without in-house installation of complex hardware infrastructure. Moreover, web-based EHR is expected to be the fastest growing product segment in the coming years
• Acute care EHR held the majority of EHR type market share at around 48% in the year 2016; whereas post-acute care EHR is likely to showcase fastest growth rate over the forecast period
• The hospital use EHR segment accounted for the largest end-use share due to the excessive adoption rate among hospitals, whereas ambulatory care EHR is expected to be the fastest growing segment
• As a part of the Health HITECH Act of 2009, the federal government allocated USD 27 billion for an incentive program, especially arranged for promoting adoption of EHR in hospitals and ambulatory care centers
• The EHR industry in Asia Pacific is projected to display substantial growth over the forecast period owing to various developments across major economies along with increased expenditure on healthcare IT. This regional market is expected to grow at a CAGR of 7% from 2017 to 2025
• According to Healthcare Information and Management Systems Society (HIMSS) analysis adoption model for EHR, more than 2.5% of total hospitals in the Asia Pacific region crossed stage 6 of EHR implementation by the end of 2016, fueling the regional market growth
• Some of the established key players in this industry include Cerner; Allscripts; McKesson Corporation; MEDITECH; Epic Systems Corporation; and NextGen Healthcare. Some of the emerging players are eClinicalWorks; Healthcare Management System; Healthland; and CureMD Healthcare; etc. 

Click Here For Access Full Report : https://goo.gl/mmMwZK

Radiation Oncology Market Worth Is Expected To Reach USD 10.1 Billion By 2025

Rising prevalence of cancer is the prime factor responsible for substantial growth of radiation oncology market over the forecast period.

Technological advancements in radiotherapy resulted in increased adoption of radiation oncology as primary treatment line of cancer. Development of compact advanced radiotherapy options such as CyberKnife, Gamma Knife, and tomotherapy complemented this growth. These advanced methods pose lesser postoperative complications and faster recovery time.

Increasing per capita healthcare expenditure is also an important macroeconomic factor driving the market growth. In addition, with the aid of supportive government initiatives and awareness, patients are not hesitant to opt for advanced treatment options. For instance, per capita health expenditure witnessed exponential growth of more than 55.0% from 1995 to 2014, as stated by the World Bank Group.

View summary of this report, Click Here 

Further key findings from the study suggest:

• External Beam Radiation Therapy (EBRT) inclusive of compact advanced radiation therapy, proton therapy, and Linear Accelerator (LINAC), held lucrative share in the product segment of radiation oncology market in 2016.
• Brachytherapy is likely to gain maximum share over the next eight years. Extensive usage of brachytherapy for the treatment of prostate and breast cancer is anticipated to govern the growth.
• EBRT applications inclusive of prostate treatment, breast, lung, colorectal, head, and neck cancer dominated application segment.
• Image Guided Radiation Therapy (IGRT) contributed to technology with around 13.0% share in 2016. In this method, overall objective is to minimize the exposure to the healthy surrounding tissue.
• 3-D CRT technology is anticipated to grow at a lucrative growth rate over the next 8 years. In this technique, radiation beams form the shape at the specific site of cancer.
• North America held maximum share in global radiation oncology market in 2016. Developed health infrastructure, presence of many multinational players, and greater per capita health infrastructure are the key factors contributing to the dominance of this region over the forecast period.
• However, uncertain health reforms post the U.S. presidential election of 2016 coupled with shortage in supply of radiopharmaceuticals is likely to hinder the growth in this region.
• Varian Medical Systems, Elekta AB, Accuray Incorporated, Ion Beam Applications SA, C.R. Bard, Inc., IsoRay, Inc., Mevion Medical Systems, Nordion (Canada) Inc., NTP, and Mallinckrodt Public Limited Company are some of the key players operating in radiation oncology market.

Click Here For Access Full Report : https://goo.gl/d5bx5w

Breast Implants Market Growth Is Anticipated To Reach USD 2.0 Billion By 2025

Increasing focus toward enhancement of physical appearance has led to the growth of breast implants market.

Breast reconstructions are being highly adopted by women in order to enhance their physical appearances. This kind of surgery involves esthetic repair of any damage taking place after implantation procedure. According to the American Society of Plastic Surgeons, in 2015, nearly 106,000 breast reconstruction procedures have been performed in the U.S. Thus, such huge number of cases are expected to drive the growth of the market.

Breast implants are used post mastectomy to enhance esthetic appeal. Breast augmentation is another procedure requiring the application of these implants. Esthetic appeal plays an important role in increasing the demand for these procedures, thereby, making the cosmetic industry lucrative for the target population.

View summary of this report, Click Here 

Further key findings from the study suggest:

• In 2016, silicone implants dominated the market due to the fact that it has a natural resemblance to the breast tissue
• Saline implants are anticipated to showcase significant growth over the forecast period due to lesser risk of complications during implant rupture
• Round-shaped implants held the largest market share in 2016 owing to less complications involved during implant rotation
• Anatomical-shaped devices are expected to showcase lucrative growth in the future due to their design that has a natural appearance, which make them ideal for breast enhancement
• The cosmetic surgery segment dominated the market in 2016 due to the growing number of cosmetic procedures conducted globally
• North America dominated the market in 2016 due to rising number of augmentation procedures of this organ conducted in the U.S.
• Asia Pacific is expected to display lucrative growth over the forecast period owing to immense opportunities in the field of medical tourism in this region
• Some of the key players include ALLERGAN; Sientra, Inc.; GC Aesthetics; Mentor Worldwide LLC; Establishment Labs S.A.; Polytech Health & Aesthetics GmbH; GROUPE SEBBIN SAS; HANSBIOMED CO. LTD; Laboratoires Arion; and Shanghai Kangning Medical Supplies Ltd.

Click Here For Access Full Report : https://goo.gl/4s8DSz

Hepatitis Hherapeutics Market Growth Is Expected To Reach USD 25.8 Billion By 2025

The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines.

Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions.

According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

View summary of this report, Click Here 

Further Key Findings From the Report Suggest:

• Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016
• In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure. 
• Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate.
• Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc.

Click Here For Access Full Report : https://goo.gl/GC3LgV

Live Cell Imaging Market Worth Is Expected To Reach USD 9.0 Billion By 2025

Rising popularity of kinetic research over fixed cellular analysis is the key driver. Addition of dyes and reagents alter the cell behavior, mostly in a negative manner, which does not showcase the natural course of action of the cellular functions. Understanding the cellular behavior in its natural state is crucial in drug discovery and targeted drug therapy. This, in turn, increases the need for live cell imaging, thus boosting the market.

In a survey by Drug Discovery World Spring, almost 21% researchers prefer & use live cell imaging and 31% plan to use it in the future. Moreover, 38% of the respondents were interested in using live cell kinetic HCS imaging in the future. The most important feature for researchers is the ability to automate the incubation and image capturing of any live cell analyzer. Secondly, they also give importance to viable cell-tracking ability of the equipment. Further development in the technology of equipment is expected to fulfill these criteria and boost the utility of the same over the forecast period.

Development in delivering probes in living cells, targeting organelles, and proteins using some of the techniques has increased use and adoption of live cell imaging in research and other applications. With improved fluorescent probes, the techniques such as Fluorescence Resonance Energy Transfer (FRET) share a majority of the share.

View summary of this report, Click Here 

Further Key Findings From The Report Suggest:

• Equipment dominated the product segment in 2016. The current system, although of great potential are still expected to perform better over the next few years. The general trend is to make the instruments compact and integrated for end-to-end processing.
• Cell biology dominated the application with more than 30% of the shares and was closely followed by developmental biology. Stem cell and drug discovery are the upcoming fields to apply live cell imaging in the research.
• North America dominated due to its high investment rate and technologically sound infrastructure. The research firms present in this region are technologically aware, hence, readily invest in high cost equipment.
• Asia Pacific is expected to show fastest growth over the forecast period due to increasing application of these imaging techniques in drug discovery and personalized medicine.
• Key players includes Carl Zeiss Meditec AG; Leica Microsystems; Nikon Corporation; Becton, Dickinson and Company; GE Healthcare; Olympus Corporation; Thermo Fisher Scientific Inc.; Sigma-Aldrich Corporation; PerkinElmer, Inc.; and Molecular Devices, LLC

Click Here For Access Full Report : https://goo.gl/meRSGy